Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Walgreens Boots Alliance delivered an upside earnings surprise when it handed down its most recent quarterly earnings report, leaving investors wondering if the pharmacy chain can do it again when it reports its third quarter fiscal 2023 results on June 27. Walgreens is expected to post earnings per share (EPS) of $1.08 according to Zacks Consensus Estimate, an improvement from the year-ago quarter when its adjusted EPS was $0.96.

Walgreens 3Q earnings await: can the pharmacy giant again top expectations?

The collaboration between Walgreens Boots (WBA) and Freenome to advance research based on the early detection of cancer.

Walgreens Boots (WBA) Aids Freenome in Early Cancer Detection

Walgreens is expanding into healthcare, and that's going to be a much bigger part of its business. The company is working on bringing its expenses down, which should improve profitability.

Where Will Walgreens Boots Alliance Be in 5 Years?

Amazon

Enbridge

SL Green Realty

AT&T

Verizon

Global X S&P 500 Covered Call ETF

The Dividend Harvesting Portfolio has reached a milestone, generating over $1,000 of annual dividend income after 119 weeks. The portfolio focuses on income generation, downside mitigation through diversification, and capital appreciation, with a strategy of allocating $100 weekly to dividend-producing investments. The Dividend Harvesting Portfolio is not meant to beat the market or replace index funds but serves as a blueprint for constructing a dividend portfolio and illustrating the benefits of consistent investing.

Dividend Harvesting Portfolio Week 119: $11,900 Allocated, $1,006.82 In Projected Dividends

DEERFIELD, Ill. & SAN FRANCISCO--(BUSINESS WIRE)--Walgreens and Freenome today announced a multi-year relationship to advance clinical studies of Freenome's blood-based tests for the early detection of cancer. Walgreens will combine its national footprint, patient insights, compliant recruitment technology and local infrastructure to engage diverse patient populations in Freenome's multi-cancer research program. “At Walgreens, our aim is to help every community we serve see clinical research as.

Walgreens and Freenome Partner to Increase Diversity in Research Focused on the Early Detection of Cancer

Walgreens Boots Alliance has been disappointing in price for almost eight years, but analysts give it a 5-star undervaluation rating and a suggested cheap buy price of $33.60. Walgreens has a 6.1% yield, a safe slowly rising dividend with a quality BBB S&P rating, making it a suitable option for income-focused investors. Walgreens' future potential seems to point to a better 2024 with synergies from its acquisitions starting to come to fruition and growth expected.

Walgreens Boots Alliance: 6% Yielding Goldilocks Income Dividend Champion

Doximity

Doximity delivers double-digit growth -- and some of the biggest healthcare players are clients. Walgreens has invested in growing in the trillion-dollar primary care market.

More Likely to 5x First: Doximity vs. Walgreens

DEERFIELD, Ill. & SAN FRANCISCO--(BUSINESS WIRE)--Walgreens is teaming up with Greater Than HIV along with community organizations to provide free HIV testing on National HIV Testing Day, June 27.

Walgreens and KFF's Greater Than HIV Team Up with Community Partners to Provide Free, Confidential HIV Testing and Counseling on National HIV Testing Day (June 27)

International Consolidated Airlines Group SA

Ofcom confirmed on Monday that it had been hit by a cyberattack by Russian hackers which affected the likes of British Airways, the BBC and Boots in early June. Data from some 412 Ofcom employees was downloaded during the attack by the Clop ransomware group, according to the broadcasting regulator.

Ofcom latest to be hit in Russian software hack

For quite a long time, Walgreens and other pharmacies have kept drugs containing ingredients that can be addictive behind locked cabinet doors.

Walgreens Takes Customers Prisoner

New Mexico reached a $500 settlement agreement with Walgreens over the pharmaceutical giant's role in the opioid epidemic, lawyers for the state said Friday.

New Mexico and Walgreens reach $500 million opioid settlement

Allergan

CVS Health

Teva Pharmaceutical

Teva, Allergan, CVS and Walgreens said enough states agreed to final agreements, adding to the billions flowing to communities.

Pharmaceutical Giants Set $19 Billion Opioid Settlement as States Debate How to Spend It

Walgreens just opened a redesigned store in a downtown Chicago neighborhood where most of the merchandise is intentionally kept out of sight.

Walgreens unveils Chicago store with only two aisles and most products kept out of sight

Walgreens Boots Alliance has agreed to pay $500 million to New Mexico to settle claims that it fueled opioid addiction in the state by failing to stop illegal pill sales, lawyers for the state announced on Friday.

Walgreens reaches $500 mln deal with New Mexico over opioid crisis

AbbVie

New York Attorney General Letitia James announced Friday the final approval of $17.3 billion in national settlement agreements with drug-store chains CVS Health Corp. CVS, and Walgreens Boots Alliance Inc. WBA, -0.68%, and with drug makers Teva Pharmaceutical Industries Ltd. TEVA, -0.61% and AbbVie Inc.'s ABBV, +0.61% Allergan.

NY AG approves $17.3 billion opioid settlement with CVS, Walgreens, Teva and AbbVie's Allergan

DALLAS--(BUSINESS WIRE)--Today, the nationally recognized attorneys at Baron & Budd, with shareholders Daniel Alberstone and Mark Pifko serving as co-lead counsel along with Peter Mougey and Jeff Gaddy from Levin, Papantonio, Rafferty; Anthony Majestro from Powell & Majestro; and Luis Robles of Robles Rael Anaya, announced a record-breaking $500 million settlement agreement with pharmaceutical giant Walgreens concerning the company's role in the opioid epidemic that has ravaged the Stat.

Baron & Budd Obtains Record $500 Million Settlement Against Walgreens in New Mexico AG Opioid Suit

Walgreens Boots Alliance has sold its remaining stake in home infusion services provider Option Care Health for proceeds of about $330 million.

In Walgreens Latest Divestiture, Drugstore Chain Sells Remaining Stake In Infusion Business

DEERFIELD, Ill.--(BUSINESS WIRE)--WBA sells remaining shares of Option Care Health for approximately $330 million of proceeds.

Walgreens Boots Alliance Sells Remaining Shares of Option Care Health for Approximately $330 Million of Proceeds

Amcor Plc

Franklin Resources

Cincinnati Financial

Chevron

Federal Realty Investment Trust

NextEra Energy

Realty Income Corp

Target

T. Rowe Price Group

V.F.

Exxon Mobil

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years. "--Kiplinger.com/Investing. 67 Aristocrats, screened as of June 6, 2023, represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 20.58%-43.58% topped-by TGT & VFC. By yield, VFC topped-all Aristocrats. Top-ten Yields from TROW, ABBV, FRT, BEN, AMCR, IBM, O, WBA, MMM, & VFC, averaged 5.15%.

4 Dividend Aristocrat Buys For June And 5 To Watch

Apple

American Express

Bank of America

Dollar General

Disney

Etsy

FedEx

Alphabet

Intuitive Surgical

Coca-Cola

MercadoLibre

Microsoft

Pinterest

PayPal

Shopify

Block

Vanguard Total World Stock ETF

Here are 10 stocks that could be excellent additions to your portfolio for years to come.

Best Stocks to Buy in June 2023

NIKE

Walgreens remains a business going through significant changes. Walt Disney has lost investor sentiment, but it might not stay down for long.

Is It Time to Buy the Dow Jones' 3 Worst-Performing May Stocks?

CVS Health could have brighter days ahead with plans to sell an underperforming unit and its acquisitions of two new businesses. Walgreens' proximity to Americans' homes could help it win share in the primary care market.

Better Buy: CVS vs. Walgreens Stock

Amgen

Cisco Systems

Dow Inc

Goldman Sachs

Intel

UnitedHealth Group

Visa

"The Dow adds a stock if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration.” - Dow Jones & Co. The highest-yield 10 stocks are June's Dogs of the Dow: KO, CSCO, GS, AMGN, CVX, IBM, DOW, MMM, WBA, and VZ, averaged a 4.79% annual yield. Thirty Dow stocks represent nine of eleven sectors. Dow Jones tracks utilities as a separate index and omits real estate. Broker top-ten target-estimated June net-gains ranged 17.45%-35.7%, topped by WBA 6/5/23.

Buy 3 June Dogs Of The Dow, Watch 4

Walgreens (WBA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

News for Walgreens Stock (WBA)